Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +7.27%. The company delivered an EPS surprise of +13.77%, with the consensus EPS estimate being $1.67.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Veklury- U.S. $108 million versus the three-analyst average estimate of $160.11 million. The reported number represents a year-over-year change of -70.3%. Product Sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change. Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change. Product Sales- HIV- Symtuza-Revenue share- U.S. $112 million versus the three-analyst average estimate of $109.94 million. The reported number represents a year-over-year change of +7.7%. Total product sales- Total: $7.54 billion versus $7.06 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change. Revenues- Royalty contract and other revenues: $33 million versus the eight-analyst average estimate of $49.91 million. The reported number represents a year-over-year change of -26.7%. Product Sales- Oncology- Cell Therapy- Yescarta- Total: $390 million versus $386.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6% change. Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the seven-analyst average estimate of $3.46 billion. The reported number represents a year-over-year change of +21.4%. Product Sales- HIV- Odefsey- Total: $336 million compared to the $314.11 million average estimate based on seven analysts. The reported number represents a change of -1.2% year over year. Product Sales- HIV- Genvoya- Total: $470 million versus the seven-analyst average estimate of $482.51 million. The reported number represents a year-over-year change of -9.1%. Product Sales- HIV- Descovy- Total: $616 million compared to the $573.59 million average estimate based on seven analysts. The reported number represents a change of +21% year over year. Product Sales- Oncology- Trodelvy- Total: $355 million versus the seven-analyst average estimate of $281.97 million. The reported number represents a year-over-year change of +18.7%. View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +6.2% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks